Literature DB >> 21670994

Probing the structural requirements of A-type Aurora kinase inhibitors using 3D-QSAR and molecular docking analysis.

Hui-Xiao Zhang1, Yan Li, Xia Wang, Yong-Hua Wang.   

Abstract

Aurora-A, the most widely studied isoform of Aurora kinase overexpressed aberrantly in a wide variety of tumors, has been implicated in early mitotic entry, degradation of natural tumor suppressor p53 and centrosome maturation and separation; hence, potent inhibitors of Aurora-A may be therapeutically useful drugs in the treatment of various forms of cancer. Here, we report an in silico study on a group of 220 reported Aurora-A inhibitors with six different substructures. Three-dimensional quantitative structure-activity relationship (3D-QSAR) studies were carried out using comparative molecular field analysis (CoMFA) and comparative molecular similarity indices analysis (CoMSIA) techniques on this series of molecules. The resultant optimum 3D-QSAR models exhibited an r (cv) (2) value of 0.404-0.582 and their predictive ability was validated using an independent test set, ending in r (pred) (2) 0.512-0.985. In addition, docking studies were employed to explore these protein-inhibitor interactions at the molecular level. The results of 3D-QSAR and docking analyses validated each other, and the key structural requirements affecting Aurora-A inhibitory activities, and the influential amino acids involved were identified. To the best of our knowledge, this is the first report on 3D-QSAR modeling of Aurora-A inhibitors, and the results can be used to accurately predict the binding affinity of related analogues and also facilitate the rational design of novel inhibitors with more potent biological activities.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21670994     DOI: 10.1007/s00894-011-1042-3

Source DB:  PubMed          Journal:  J Mol Model        ISSN: 0948-5023            Impact factor:   1.810


  42 in total

1.  SAR and inhibitor complex structure determination of a novel class of potent and specific Aurora kinase inhibitors.

Authors:  Nicola M Heron; Malcolm Anderson; David P Blowers; Jason Breed; Jonathan M Eden; Stephen Green; George B Hill; Trevor Johnson; Frederic H Jung; Helen H J McMiken; Andrew A Mortlock; Andrew D Pannifer; Richard A Pauptit; Jennifer Pink; Nicola J Roberts; Siân Rowsell
Journal:  Bioorg Med Chem Lett       Date:  2005-12-05       Impact factor: 2.823

Review 2.  Discovery and development of aurora kinase inhibitors as anticancer agents.

Authors:  John R Pollard; Michael Mortimore
Journal:  J Med Chem       Date:  2009-05-14       Impact factor: 7.446

3.  Discovery, synthesis, and in vivo activity of a new class of pyrazoloquinazolines as selective inhibitors of aurora B kinase.

Authors:  Andrew A Mortlock; Kevin M Foote; Nicola M Heron; Frédéric H Jung; Georges Pasquet; Jean-Jacques M Lohmann; Nicolas Warin; Fabrice Renaud; Chris De Savi; Nicola J Roberts; Trevor Johnson; Cyril B Dousson; George B Hill; David Perkins; Glenn Hatter; Robert W Wilkinson; Stephen R Wedge; Simon P Heaton; Rajesh Odedra; Nicholas J Keen; Claire Crafter; Elaine Brown; Katherine Thompson; Stephen Brightwell; Liz Khatri; Madeleine C Brady; Sarah Kearney; David McKillop; Steve Rhead; Tony Parry; Stephen Green
Journal:  J Med Chem       Date:  2007-03-21       Impact factor: 7.446

4.  Molecular similarity indices in a comparative analysis (CoMSIA) of drug molecules to correlate and predict their biological activity.

Authors:  G Klebe; U Abraham; T Mietzner
Journal:  J Med Chem       Date:  1994-11-25       Impact factor: 7.446

5.  Overexpression of aurora kinase A in mouse mammary epithelium induces genetic instability preceding mammary tumor formation.

Authors:  X Wang; Y-X Zhou; W Qiao; Y Tominaga; M Ouchi; T Ouchi; C-X Deng
Journal:  Oncogene       Date:  2006-05-22       Impact factor: 9.867

6.  Crystal structure of aurora-2, an oncogenic serine/threonine kinase.

Authors:  Graham M T Cheetham; Ronald M A Knegtel; Joyce T Coll; Suzanne B Renwick; Lora Swenson; Peter Weber; Judith A Lippke; Douglas A Austen
Journal:  J Biol Chem       Date:  2002-09-16       Impact factor: 5.157

7.  Antitumor activity of MLN8054, an orally active small-molecule inhibitor of Aurora A kinase.

Authors:  Mark G Manfredi; Jeffrey A Ecsedy; Kristan A Meetze; Suresh K Balani; Olga Burenkova; Wei Chen; Katherine M Galvin; Kara M Hoar; Jessica J Huck; Patrick J LeRoy; Emily T Ray; Todd B Sells; Bradley Stringer; Stephen G Stroud; Tricia J Vos; Gabriel S Weatherhead; Deborah R Wysong; Mengkun Zhang; Joseph B Bolen; Christopher F Claiborne
Journal:  Proc Natl Acad Sci U S A       Date:  2007-02-23       Impact factor: 11.205

8.  The discovery of the potent aurora inhibitor MK-0457 (VX-680).

Authors:  David Bebbington; Hayley Binch; Jean-Damien Charrier; Simon Everitt; Damien Fraysse; Julian Golec; David Kay; Ronald Knegtel; Chau Mak; Francesca Mazzei; Andrew Miller; Michael Mortimore; Michael O'Donnell; Sanjay Patel; Francoise Pierard; Joanne Pinder; John Pollard; Sharn Ramaya; Daniel Robinson; Alistair Rutherford; John Studley; James Westcott
Journal:  Bioorg Med Chem Lett       Date:  2009-05-03       Impact factor: 2.823

9.  VX-680, a potent and selective small-molecule inhibitor of the Aurora kinases, suppresses tumor growth in vivo.

Authors:  Elizabeth A Harrington; David Bebbington; Jeff Moore; Richele K Rasmussen; Abi O Ajose-Adeogun; Tomoko Nakayama; Joanne A Graham; Cecile Demur; Thierry Hercend; Anita Diu-Hercend; Michael Su; Julian M C Golec; Karen M Miller
Journal:  Nat Med       Date:  2004-02-22       Impact factor: 53.440

10.  Modulation of kinase-inhibitor interactions by auxiliary protein binding: crystallography studies on Aurora A interactions with VX-680 and with TPX2.

Authors:  Baoguang Zhao; Angela Smallwood; Jingsong Yang; Kristin Koretke; Kelvin Nurse; Amy Calamari; Robert B Kirkpatrick; Zhihong Lai
Journal:  Protein Sci       Date:  2008-07-28       Impact factor: 6.725

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.